Sam Anderson
Founder & CEO, Ailva
Sam Anderson — Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine
Austin, TX
Sam Anderson is the founder and CEO of Ailva, a clinical intelligence platform built by Scrivly, Inc. in Austin, Texas. He started Ailva to close the gap between what medicine knows and what a physician can actually reach during a twelve-minute visit — the structural delay that keeps landmark trial evidence out of everyday care for years at a time.
Before Ailva, Sam served as Director of Research for a consumer health publisher, where he commissioned and edited more than two hundred medically reviewed articles on topics ranging from endocrinology to sports medicine. He is also Editor-in-Chief of EudaLife Magazine, a publication focused on evidence-based health writing for general readers.
He lives in Austin, Texas, and writes about evidence-based medicine, clinical reasoning, and the practical realities of translating trial data into bedside decisions. You can reach him at contact@ailva.ai.
Recent articles
Evidence-Based Medicine
KDIGO 2026 CKD Guidelines: Key Updates for Nephrology Practice
The 2026 KDIGO guidelines introduce significant changes to CKD staging, SGLT2 inhibitor recommendations, and GLP-1 agonist integration. Here is what changed and what it means for your patients.
April 14, 2026 · 7 min read
Evidence-Based Medicine
SGLT2 Inhibitors in Heart Failure: Evidence, Dosing, and Clinical Decision Points
DAPA-HF and EMPEROR-Reduced established SGLT2 inhibitors as foundational HFrEF therapy. DELIVER and EMPEROR-Preserved extended the benefit to HFpEF. Here is the trial-by-trial evidence and practical prescribing guidance for your heart failure patients.
April 14, 2026 · 8 min read
Clinical AI
Immunotherapy Checkpoint Inhibitors: A Clinical Guide for Oncologists
PD-1, PD-L1, and CTLA-4 inhibitors have transformed solid tumor oncology. This guide covers approved indications, biomarker selection, immune-related adverse event management, and combination strategies across major tumor types.
April 14, 2026 · 8 min read
Clinical Reasoning
Sepsis Management: From Early Recognition to Evidence-Based Resuscitation
The Surviving Sepsis Campaign 2024 guidelines refined the approach to sepsis resuscitation, antibiotic timing, and vasopressor selection. This review covers the current evidence for hour-1 bundle compliance, fluid strategy, and organ support.
April 14, 2026 · 8 min read
Methodology
Treatment-Resistant Depression: Augmentation Strategies and Emerging Therapies
One-third of patients with major depressive disorder do not respond to first-line antidepressants. This review covers evidence-based augmentation strategies including lithium, atypical antipsychotics, ketamine/esketamine, and psilocybin-assisted therapy.
April 14, 2026 · 8 min read
Evidence-Based Medicine
Type 2 Diabetes Management 2026: ADA Standards of Care Updates
The 2026 ADA Standards of Care introduce updated guidance on GLP-1 agonist and GLP-1/GIP dual agonist positioning, cardiovascular risk reduction, and technology-assisted management. Key changes for primary care and endocrinology practice.
April 13, 2026 · 8 min read